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Abstract
The inducible cyclooxygenase isoform (COX-2) is associated with inflammation, tumorigenesis, as well as with physiological
events. Despite efforts deployed in order to understand the biology of this multi-faceted enzyme, much remains to be
understood. Nucleobindin (Nuc), a ubiquitous Ca
2+-binding protein, possesses a putative COX-binding domain. In this
study, we investigated its expression and subcellular localization in human neutrophils, its affinity for COX-2 as well as its
possible impact on PGE2 biosynthesis. Complementary subcellular localization approaches including nitrogen cavitation
coupled to Percoll fractionation, immunofluorescence, confocal and electron microscopy collectively placed Nuc, COX-2,
and all of the main enzymes involved in prostanoid synthesis, in the Golgi apparatus and endoplasmic reticulum of human
neutrophils. Immunoprecipitation experiments indicated a high affinity between Nuc and COX-2. Addition of human
recombinant (hr) Nuc to purified hrCOX-2 dose-dependently caused an increase in PGE2 biosynthesis in response to
arachidonic acid. Co-incubation of Nuc with COX-2-expressing neutrophil lysates also increased their capacity to produce
PGE2. Moreover, neutrophil transfection with hrNuc specifically enhanced PGE2 biosynthesis. Together, these results identify
a COX-2-associated protein which may have an impact in prostanoid biosynthesis.
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Introduction
Cyclooxygenase (COX) mediates a critical metabolic step in
prostanoid biosynthesis. The inducible isoform, COX-2, largely
predominates over the constitutive isoform, COX-1, in the
production of prostaglandin (PG)E2 and thromboxane (TX)A2 in
inflammatory cells including neutrophils [1–4]. PGE2 and TXA2
biosynthesis in neutrophils is initiated by the release of esterified
arachidonic acid (AA) by type IV cytosolic (c)PLA2 [5–8]. COX-2
then catalyzes two reactions by which AA is transformed into
PGH2, the common precursor to all prostanoids. PGH2 can be
isomerized in PGE2, either non-enzymatically [9], or by the
microsomal PGE2 synthase (mPGES)-1 isoform [8], while
formation of TXA2 chiefly results from TXA2 synthase activity.
It is well-established that PGE2 is implicated in pain, vasodilation
and eodema. On the other hand, PGE2 inhibits major inflamma-
tory responses of phagocytes. In neutrophils, PGE2 can prevent
chemotaxis, aggregation, superoxide production, lysosomal en-
zyme release and generation of leukotriene B4 [4,10–14].
The COX-2 enzyme has generated particular interest for its
implication in inflammation, cellular proliferation, differentiation
and tumorigenesis, [15,16], and has recently emerged as a
therapeutic target in the treatment and prevention of human
cancers [17–20]. Also, COX-2 mediates physiological events such
as kidney functions, post-natal development and female repro-
ductive processes [21–23]. In spite of the pivotal roles of COX-2 in
many aspects of biology, much remains to be discovered around
the regulation of its activity in inflammatory cells. In particular,
proteins that associate with COX-2 have yet to be identified.
Nucleobindin (Nuc) is a ubiquitous protein featuring multiple
putative functional domains, indicating its potential implication in
a number of cellular processes [24–28]. As such, Nuc has been the
focus of reports originating from diverse fields including
autoimmunity [29], intracellular signaling [30], osteogenesis
[26], cancer [31] and inflammation [27]. At the protein level,
Nuc is constituted of 460 amino acids, including an N-terminal 25
amino acid signal peptide responsible for its initial localization to
the endoplasmic reticulum (ER) [32]. In addition, Nuc contains
several classical interaction domains: a DNA binding site, a
heterodimerization domain, two EF-hand Ca
2+-binding sites, a
nuclear localization signal [24–26] as well as non-classical protein-
protein interaction domains including a G-protein-binding region
and an high affinity COX-binding domain, as evidenced by a
yeast two-hybrid assay [27,28]. Depending on the model at hand,
Nuc has been detected in various subcellular structures such as the
nucleus [31,33], mitochondria [34] the cytoplasm [34–37], the
endoplasmic reticulum (ER) [33,34,36] and the Golgi apparatus
[35]. The Golgi, like the ER, plays a role as an intracellular Ca
2+
reservoir, which can be released in the cytosol in response to
various stimuli, in turn activating a number of intracellular
signaling cascades [38]. As such, Nuc may be involved in
establishment of the agonist-mobilizable Golgi Ca
2+ store [30].
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relatively well-characterized capacity to bind Ca
2+ [36], the
biological functions of Nuc remain elusive.
In the present study, we investigated the expression of Nuc, its
subcellular localization, its expression and affinity for COX-2, as
well as its impact on COX-2-dependent PGE2 biosynthesis in
human neutrophils. Results obtained identify Nuc as a COX-2-
associated protein which may have a role in the biosynthesis of
prostanoids.
Methods
Experimental Procedures
Materials. LR White was obtained from Reading (England).
Polyclonal anti-albumin goat antibody was from CN Biosciences
(La Jolla, CA, USA). Polyclonal anti-lactoferrin antibody was from
Sigma (Oakville, ON, Canada). Monoclonal anti-GRP-78 was
from BD Biosciences (Franklin Lakes, NJ, USA). Polyclonal anti-
58k Golgi antibody was from Abcam Inc. (Cambridge, MA, USA).
Polyclonal anti TXA2-synthase and monoclonal anti-COX-2
antibodies were from Cayman Chemical (Ann Arbor, MI, USA).
Polyclonal anti-COX-2 antibodies were from BIOMOL
International, L.P., (Plymouth meeting, PA, USA).
Cloning and purification. Full-length human Nuc was
amplified using Expand HIFI+ DNA polymerase (Roche, Laval,
Qc, Canada) from pOTB7/Nucleobindin clone (ID 2821805
produced by Invitrogen Life Technologies, Carlsbad, CA, USA).
PCR reactions (35 cycles; annealing temp. 60uC) were performed
using the following primers: 59-GGA ATT TCA TAT GCC TCC
CTC TGG-39 (forward) and 59-CCT AGC TCA TAT GTC ACA
GAT GCT GG-39 (reverse); yielding a PCR product of 1409 bp in
length. pET/NucDCBD was amplified from pET/Nuc using same
DNA polymerase. PCR reaction (30 cycles; annealing temp. 60uC)
was performed using the following primers: 59-GGA ATT ACA
TAT GAG TCC CGA CAC AGG-39 (forward) and 59-CCT
AGC TCA TAT GTC ACA GAT GCT GG-39 (reverse); yielding
a PCR product of 1283 bp in length. Sequences of amplified
fragments were confirmed by DNA sequencing. The cDNA
products were cloned into the NdeI restriction site of pET-15b
(Novagen, San Diego, CA, USA). BL21 cells were transformed
with pET-15b/Nuc or pET/NucDCBD expression vectors and
induced with 1 mM isopropyl-1-thio-b-D-galactopyranoside
(Tekniscience, Terrebonne, Qc, Canada). Bacterial extracts were
processed for protein purification using a His-Bind Resin column
and buffer kit (Novagen).
Production of polyclonal antibodies against nucleo-
bindin. Rabbits were injected with an emulsion of 50–100 mg
hrNuc and complete Freund’s adjuvant. Total IgGs were purified
using a Protein G-coupled sepharoseH 4f a s tf l o wc o l u m n( G E
Healthcare, Waukesha, WI, USA).
Human leukocyte isolation. Neutrophils were isolated as
originally described [39] with modifications [4]. Viability was
greater than 98%, as determined by trypan blue dye exclusion.
Cell incubations. Neutrophils were resuspended at a con-
centration of 5610
6 cells/ml (25610
6 cells/ml in experiments
where RNA was to be extracted) in Hank’s balanced salt solution
(HBSS; 37uC) containing 10 mM HEPES pH 7.4, 1.6 mM Ca
2+,
no Mg
2+ and the following antiprotease cocktail: 0.2 mg/ml
diisopropylfluorophosphate (Serva Electrophoresis, Heidelberg,
Germany), 10 mg/ml leupeptin, 10 mg/ml aprotinin (ICN
Biomedicals Inc., Irvin, CA, USA).
PGE2 synthesis. In purified enzyme-based assays, 1.0 U
hrCOX-2/sample were used (Cayman Chemicals) in HBSS 16
supplemented with Heme, in a final volume of 200 ml. Where
indicated, hrNuc was added and samples were incubated for
15 min at 37uC. AA (10 mM final) was added and samples were
incubated for 30 min at 37uC. Reactions were stopped by placing
samples on ice-cold water. Samples were assayed for their content
in PGE2 by ELISA (Assay Designs, Brockville, ON, Canada).
Cross-reactivities in the PGE2 ELISA were ,0.04% for 6-keto
PGF1a, and ,0.01% for LTB4, TXB2, and AA.
In cell-based assays, neutrophils stimulated with GM/TNF for
2 h were pelleted and resuspended in 700 ml ice-cold HBSS
containing the anti-protease cocktail. Suspensions were sonicated
on ice and centrifuged (30006 g). Cellular extract aliquots (5 ml)
were incubated with hrNuc in a total of 200 ml for 15 min at 37uC,
before stimulation with AA (10 mM final) for 30 min at 37uC.
Reactions were stopped on ice-cold water; samples were briefly
Figure 1. Expression of Nuc in human neutrophils. A) Real-time
PCR determination of Nuc, COX-1 and COX-2 messenger RNA
expression in neutrophils. Cells were stimulated for 60 min with
lipopolysaccharide (LPS ; 100 ng/ml), a mixture of granulocyte/
monocyte colony stimulation factor and tumor necrosis factor-a (GM/
TNF; 1.4 nM and 100 ng/ml respectively), formyl-methionyl-leucyl-
phenylalanine (fMLP; 100 nM) or with PMA (10 nM). Samples were
processed for the determination of GAPDH, COX-1, COX-2 and Nuc
mRNA expression by real-time-PCR. Shown are integrated results from
n=4 (6SEM) separate experiments performed in identical conditions
with different donors. B) Nuc protein expression in neutrophils, as
determined by western immunoblotting. Cells were incubated for 2 h
with diluent (saline), or with GM/TNF. Samples were processed for the
determination of Nuc expression by western immunblotting. Nuc is
constitutively present in unstimulated neutrophils. Note that hrNuc
migrated slightly slower than neutrophil native Nuc, due to the
presence of the signal peptide and of the additional His-Tag sequence.
Shown is one immunoblot, representative of four identical experiments
performed with different donors.
doi:10.1371/journal.pone.0002229.g001
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PGE2 by ELISA.
Nitrogen cavitation. The procedure was conducted essentially
as described [40], with modifications. For each cell preparation, 18
fractions were generated (1 ml each), starting from the bottom of the
tube. This procedure allows the distinct separation of azurophil
granules, specific granules, gelatinase granules, secretory vesicles, a
plasmamembrane-enriched fraction, and cytosol [40]. Eachfraction
was re-centrifuged (100 0006 g, 90 min) in a Beckman TL 100
ultracentrifuge, using a TL 100.2 rotor, in order to pellet Percoll.
Fractions (50 ml) were carefully aspirated with a pipet and processed
for western immunoblot analysis.
Western immunoblots. Samples, resuspended in sample
buffer 16 (62 mM Tris-HCl, pH 6.8, 2% SDS, 2.5% b-
mercaptoethanol, 10% glycerol, with antiprotease cocktail), were
subjected to 10% SDS-PAGE and transferred to Immobilon
membranes (Millipore Corp., Bedford, MA, USA). The
membranes were soaked for 30 min at RT in Tris-buffered saline
(TBS: 25 mM Tris-HCl pH 7.6, 0.2 M NaCl, 0.15% Tween 20)
containing 5% (w/v) dried milk, and exposed for 60 min with the
first antibody. Membranes were then washed twice in TBS, and
incubated for 30 min with a 1:10 000 dilution of a horseradish
peroxidase (HRP)-linked donkey anti-rabbit antibody (Biocan
Scientific, Mississauga, ON, Canada), or HRP-linked sheep anti-
mouse antibody (GE Healthcare). Enzyme expression was revealed
with ECL-Plus (Perkin Elmer, Boston, MA, USA).
Immunofluorescence. Neutrophils were fixed in 4%
paraformaldehyde for 20 min, then washed twice with PBS. Cell
suspensions were laid onto poly-L-lysine-coated glass slides and
allowed to air-dry. Slides were incubated with a permeabilization
buffer (0.5% NP-40, 5% heat-inactivated fetal bovine serum (FBS)
and 5% heat-inactivated donkey serum in PBS) for 5 min, washed
three times in washing buffer (5% FBS, 0.05% NP-40 in PBS),
incubated with a blocking buffer (10% FBS and 10% donkey
serum in PBS) for 30 min and washed three times prior to a 1 h
incubation with an anti-Nuc antibody (diluted 1/150 in: PBS with
5% FBS, 5% donkey serum and 0.05% NP-40) in a humid
environment. After washes, slides were incubated with goat anti-
Figure 2. Neutrophil subcellular fractionation and localization of Nuc. A) Resting (left panel) or GM/TNF-stimulated (right panel) neutrophils
were processed for cavitation and subcellular fractionation, as described in Experimental procedures. Nuc and COX-2 co-localized in ER/Golgi-
containing fractions, as determined by western immunoblotting. B) In GM/TNF-stimulated neutrophils, samples were processed as in A) for the
determination of the indicated proteins. C) In GM/TNF, and GM/TNF+fMLP (100 nM) stimulated neutrophils, samples were processed as in A) for the
determination of the indicated proteins. In each panel, all immunoblots originate from the same membrane. Shown is one immunoblot,
representative of four identical experiments performed with different donors. GRP-78: ER/Golgi marker; lactoferrin: marker of specific granules;
albumin; marker of secretory vesicles; 58k: 58k Golgi protein (Golgi marker); mPGES-1: microsomal prostaglandin E2 synthase-1; TXA2-Synthase:
thromboxane A2 synthase; cPLA2: Type IV cytosolic phospholipase A2. D) Schematized protein structure of human Nuc and putative functional
domains. The main characterized domains found in Nuc are: a signal peptide directing the protein to the ER; a COX-binding site; a putative nuclear
localization signal embedded in to a DNA-binding site; two EF-hand Ca2+-bindins sites; a leucine zipper region.
doi:10.1371/journal.pone.0002229.g002
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diluted 1/200) for 30 min in the dark, in a humid environment.
Slides were washed once and then incubated with DAPI
0.7 mmoles/ml (Molecular Probes) or with 250 ng/ml propidium
Iodine (PI; Sigma) for 5 min in the dark. Slides were washed in
PBS and prepared for microscopy with Gel/Mount
TM (Biomeda,
Foster City, CA, USA). Images were captured by a CoolSNAP
HQ camera mounted on an Olympus BX-51 upright microscope
using a 606UPlan Apo objective, and processed with ImagePro
4.5.1 software (Media Cybernetics, Silver Spring, MD, USA).
Confocal microscopy was performed on an Olympus BX-61
microscope using a UPlan Apo 1006objective with immersion oil.
Data was collected with the FluoView software (Olympus).
Movie S1: The 3D representation was generated with confocal
microscopy images, using ImageJ (http://rsb.info.nih.gov/ij) and
edited with iMovie HD (Apple Computer Inc.).
Immunogold labeling and electron microscopy. Following
stimulation with GM/TNF, cells were fixed for 24 h in a solution
0.1 M cacodylate buffer [Na(CH3)2AsO2?3H2O], pH 7.3,
containing freshly prepared 4% paraformaldehyde and 0.2%
glutaraldehyde. Fixed cells were then washed 3 times with 0.1 M
cacodylate buffer pH 7.3 and dehydrated in ethyl alcohol by
gradually increasing the specimen’s ethyl alcohol concentration
(30%, 50%, 70% and 90%, 10 min twice per concentration). The
specimen were infiltrated with LR White (LR White/90% ethanol
1:1 mixture) 2 h at RT, overnight at 4uC and 2 times 2 h at RT. LR
White polymerization was triggered by subjecting the specimen to
U.V. light for 48 h at 4uC. Embedded specimens were cut into
ultrathin sections (80 nm), then laid on Ni/fomvar grids. Grids were
blocked with PBS 16+ 5% BSA for 30 min, RT and washed with
PBS 16+ 1% BSA + 0.1% Tween-20. Grids were deposited face
downona50 mldropofantibodysolution.Incubationswithprimary
antibodies (rabbit polyclonal anti-Nuc, 1/50; chicken polyclonal
anti-Nuc, 1/100 000, Genway Biotech, San Diego, CA, USA);
polyclonal anti-COX-2 (1/50, Santa Cruz Biotechnologies, Santa
Cruz, CA, USA); polyclonal anti-GRP-94 (1/400, Abcam Inc.) were
done overnight at 4uC, whereas incubations with secondary
antibodies, either 18 nm colloidal Gold-AffiniPureH donkey anti-
chickenIgYor6 nmcolloidalGold-AffiniPureHgoatanti-rabbitIgG
(Jackson Immunoresearch Labs., West Grove, PA, USA), were done
at RT for 4 h. The double labeling was performed in a serial fashion
starting with the Nuc labeling followed by the COX-2 labeling.After
eachantibodyincubation,gridswerewashedwith561m lP B S1 6+
1% BSA + 0.1% tween20. Following the last antibody incubation,
the grids were washed with 561m ld H 2O. Finally, the dried grids
were stained with uranyl acetate. Analyses were performed on a
JEOL JEM-1230 transmission electron microscope (JEOL,
Montreal, QC, Canada). Magnifications were between 10 0006
and 120 0006.
Immunoprecipitations with magnetic beads. Anti-Nuc
antibodies generated in-house, or irrelevant IgGs, were coupled to
Dynabeads M-500 subcellular (Dynal, Norway). Immunomagnetic
beads were incubated with selected subcellular fractions at a ratio
of 10 ml fraction/5 million beads/ml in PBS pH 7.4, 2 mM
EDTA, 5% BSA and the anti-protease cocktail, for 12 h at 4uC.
Beads were magnetically immobilized and supernatants were
discarded. The beads were washed three times in PBS pH 7.4,
2 mM EDTA, anti-protease cocktail, with decreasing
concentrations of BSA (5%, 0.1%, 0%), then resuspended in
sample buffer 16and boiled for 2–3 min.
Pull-down assay. hrNuc was coupled to CNBr-activated
SepharoseH 4B beads (GE Healthcare). PMA-stimulated cells were
pelleted (microfuge) and resuspended in 0.1% NP-40 lysis buffer
[41] for 10 min at 4uC. The lysates were centrifuged at 10006g
for 10 min at 4uC. In this procedure, COX-2 is mainly located in
the non-nucleus fraction, which was used for the present assay.
Supernatants were incubated with 50 ml of hrNuc-coupled
sepharose beads, or with inactivated sepharose beads for 2 h,
RT. After incubation, beads were centrifuged (30 sec, 15006 g),
washed twice with HBSS + CaCl2 + antiprotease cocktail,
resuspended in sample buffer 16and heated 2–3 min at 95uC.
Immunoprecipitations under native conditions.
Immunoprecipitations were performed as described earlier [42],
with modifications. Briefly, neutrophils stimulated with GM/TNF
were centrifuged, and the cell pellets were lysed by adding cold lysis
buffer (10 mM Tris-HCl, pH 7.4, 137.2 mM Nacl, 1 mM EDTA,
0.6% CHAPS, 2 mM orthovanadate, and the protease inhibitor
cocktail) for 5 min on ice. The insoluble material was discarded after
centrifugation at 13 0006ga t4uC during 5 min. The supernatant
was harvested, then precleared with protein A-Sepharose at 4 uCf o r
30 min. Resulting supernatants were incubated at 4 uC either with
8 mg of anti-COX2 (mouse) antibodies or 8 mgo fa n t i - N u c( r a b b i t )
antibodies for 1 h followed by 2 h incubation with protein A-
Sepharose beads. The beads were collected and washed three times
Figure 3. Subcellular localization of Nuc in neutrophils, as
assessed by indirect immunofluorescence and confocal mi-
croscopy. Resting neutrophils were processed for the detection of Nuc
by immunofluorescence, as described in Experimental Procedures. A)
Nuclei were stained in blue. Immunoreactive Nuc, in green, was mainly
observed in the center of cells, typically as two to three main spots
between nuclear lobes and, to a lesser extent, within the cytoplasm. Left
panel: with anti-Nuc antibody. Right panel: anti-Nuc antibody was
omitted. B) For confocal microscopy experiments, the nucleus was
stained with propidium iodine and appeared red-orange; darker regions
are distinctive of euchromatin; immunoreactive Nuc, in green, appeared
at the center of the cell. Left panel: composite confocal image; most of
the immunoreactive Nuc was at the center of the cell, with a limited
number of smaller spots also in the vicinity of the nucleus. Right panel,
(from left to right, top to bottom): represented are 9 equidistant slices
from the composite image shown in left panel.
doi:10.1371/journal.pone.0002229.g003
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beads, which were boiled for 7 min.
Transfection of recombinant nucleobindin. We used the
Pro-Ject Protein Transfection Reagent (Pierce, Rockford, IL),
according to the manufacturer’s instructions. Briefly, neutrophils
were stimulated with GM-CSF/TNF-a at 37uC. After 15 min, a
mixture of 7.5 ml of the reagent with 2 mg of the protein (Nuc or
NucDCBD) were added and incubated for 4 h at 37uC. AA
(10 mM) was added and samples were incubated for an additional
30 min at 37uC. Samples were centrifuged and supernatants were
assayed for PGE2 content by ELISA. Cell pellets were processed
for SDS-PAGE.
Statistical analysis. Where applicable, statistical analysis
was performed by Student’s non-paired t-test (two-tailed), and
significance (*, **) was considered attained when p was ,0.05.
Results
Nucleobindin is constitutively expressed in human
phagocytes
Expression of Nuc in neutrophils was first assessed. To this end,
cells were incubated with agonists known to stimulate inflammatory
gene expression in these cells: lipopolysaccharide (LPS), the
formylated synthetic peptide fMLP, the phorbol ester PMA, or a
mixture of granulocyte-macrophage colony-stimulating factor and
tumor necrosis factor-a (GM/TNF). Following stimulations, mRNA
levels of COX-1, COX-2 and Nuc were determined by real-time
PCR. While each of the agonists elicited an increase in expression of
COX-2 mRNA, as previously reported [3,43], that of Nuc only
varied in a modest fashion and, in most conditions, variations were
comparable to that of COX-1, a constitutively-expressed gene in
neutrophils (Fig. 1A). Similar results were obtained in human
monocytes stimulated with LPS (data not shown). These results are
consistent with the reported structure for the promoter region of the
Nuc gene, featuring typical elements of house-keeping genes [32].
Data obtained at the protein level also indicate that resting
neutrophils constitutively express Nuc (Fig. 1B).
Nuc and COX-2 are localized in the Golgi and ER of
neutrophils
The subcellular localization of Nuc, and of the enzymatic
machinery responsible for prostaglandin biosynthesis was investi-
gated in human neutrophils. To this end, we used the nitrogen
cavitation technique coupled to fractionation on a PercollH density
Figure 4. Demonstration of co-localization for Nuc and COX-2 in neutrophils, by electron microscopy. Neutrophils stimulated with GM/
TNF were processed for the detection of Nuc (A), COX-2 (B) and Golgi (C), by indirect immunostaining and electron microscopy. For each protein,
labeling was mainly found in a single cluster situated between nuclear lobes, in the center of the cell. D) Samples were processed for the double
detection of Nuc and of COX-2 by electron microscopy. To this end, a polyclonal chicken anti-Nuc antibody and a polyclonal rabbit anti-COX-2
antibody, were used in sequence, as described in the Experimental procedures. Co-localization of Nuc (18 nm beads, indicated by thick arrows) and
COX-2 (6 nm beads, thin arrows) is clearly seen in a cluster between nuclear lobes. In each panel, a single neutrophil is shown in the upper-left corner;
the magnified region of interest is represented by the respective white square.
doi:10.1371/journal.pone.0002229.g004
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separation of intracellular compartments such as: four distinct
populations of granules, secretory vesicles, plasma membranes and
the cytosol [44]. Neutrophils were stimulated for 2 h with GM/
TNF, a condition which efficiently up-regulates their expression of
COX-2 [3]. Following stimulation, cells were processed for
nitrogen cavitation, subcellular fractionation, and detection of
proteins of interest by western immunoblotting. The fractionation
pattern was validated with the use of specific cellular compartment
markers. Lactoferrin, a marker of specific granules, was predom-
inantly found in fractions 6 to 8, whereas albumin, the marker for
secretory vesicles, was predominantly in fractions 9 to 11 (Fig. 2A),
in accordance with previous reports [44,45]. Nuc was mainly found
in fraction 11, both in diluent- and in GM/TNF-stimulated cells.
When COX-2 was up-regulated, it co-localized with Nuc, in the
fractions 10 to 12 of GM/TNF-stimulated cells (Fig. 2A, right panel)
and also with the glucose-related protein (GRP)-78, marker for Golgi
and ER structures. Localization patterns of Nuc, COX-2 and GRP-
78 systematically matched with each other, suggesting that Nuc and
COX-2 both reside in the Golgi and ER structures [44].
Additional fractionation experiments were performed with
GM/TNF-stimulated neutrophils in order to localize additional
enzymes implicated in prostanoid synthesis. Microsomal PGE2-
synthase-1, thromboxane-synthase, as well as 58k, an additional
marker for the Golgi, also co-localized with COX-2 and Nuc-
positive fractions (Fig. 2B). For the specific case of type IV cytosolic
phospholipase A2 (cPLA2), GM/TNF-treated cells were stimulated
with fMLP prior to the fractionation process in order to induce its
phosphorylation and translocation to membranes [41]. In this
situation, cPLA2 was readily detected in COX-2- and Nuc-
containing fractions (Fig. 2C).
Nuc and COX-2 are localized in proximity of each other in
neutrophils
Results obtained so far suggest a Golgi and ER localization for
Nuc and for the enzymatic machinery mediating prostanoid
synthesis. We sought further confirmation for this co-localization
in intact cells, by immunofluorescence, confocal micrscopy, and
electron microscopy. For immunofluorescence experiments, rest-
ing neutrophils were fixed and permeabilized, then processed for
the detection of Nuc by indirect labeling. As can be appreciated in
Fig. 3A (left panel), immunoreactive Nuc (green labeling) appeared
predominantly embedded near the center of the cells and between
nuclear lobes, typically with one or two main spots per cell and a
small number of secondary spots, a pattern consistent with a Golgi
and ER localization [46]. Analysis of the samples by confocal
microscopy further precised the central location of Nuc within the
cell (Fig. 3B). A 3D representation of the confocal data (Movie S1)
nicelyillustratesthe centrallocalizationofNucwithinthe neutrophil,
consistent with its Golgi and ER localization. In electron microscopy
experiments, intact neutrophils stimulated with GM/TNF were
fixed and embedded; ultrathin slices were incubated with specific
polyclonal antibodies for the detection of Nuc (Fig. 4A), COX-2
(Fig.4B)ortheGolgimarkerGRP-94(Fig.4C).Foreachofthethree
proteins, labeling was found mainly clustered in a central area
localized in the vicinity of nuclear lobes, and in a small number of
secondary sites, largely confirming the immunofluorescence and
confocal microscopy data and supporting the idea that Nuc and
COX-2 both localize in the Golgi and ER. In a separate set of
experiments, samples were subjected to a double-labeling and
prepared for electron microscopy showed proximity between COX-
2 and Nuc (Fig. 4D). The pattern of labeling demonstrated that both
proteins can be located very close to each other, clustered on the
luminal side of vesicular structures (Nuc, thick arrows; COX-2, thin
Figure 5. Direct interaction between neutrophil Nuc and COX-
2. A) Nuclear-free extracts from unstimulated or PMA-stimulated
neutrophils were incubated with sepharose beads linked to hrNuc for a
pull-down assay, then processed for western immunoblotting for the
detection of COX-2. Lane 1: whole cells, lane 2: nucleus-free extracts,
lane 3: nucleus-free extracts incubated with sepharose beads linked to
hrNuc (Seph-Nuc). B) Nuclear-free extracts from PMA-stimulated cells
were processed as in A), in presence of 1.5 mM Ca
2+ (left panel) or in
presence of 5 mM EGTA (right panel; without Ca
2+). Lane 1: whole cells,
lane 2: nucleus-free extracts, lane 3: nucleus-free extracts incubated
with inactivated sepharose beads, lane 4: nucleus-free extracts
incubated with sepharose beads linked to hrNuc (Seph-Nuc). For each
panel, results shown are from one experiment, typical of two separate
experiments performed in identical conditions with different donors. C)
Immunomagnetic beads coated with anti-Nuc IgGs or with irrelevant
IgGs were incubated with an aliquot from the positive fractions (10 to
12) showed in Fig. 1. Anti-Nuc-coated beads immunoprecipitated a
structure that was positive for COX-2 and GRP-78. Results are from one
experiment, representative of n=3 distinct experiments performed in
identical conditions. D) Left panel: Nuc was immunoprecipitated from
COX-2-expressing neutrophils, using anti-Nuc or irrelevant anti-IgG
antibodies, as described in the Experimental procedures; samples were
processed for the detection of COX-2 by western immunoblot. Right
panel: COX-2 was immunoprecipitated using anti-COX-2 or irrelevant
anti-IgG antibodies and samples were processed for the detection of
Nuc by western immunoblot (IP: Immunoprecipitation; WB: western
immunoblot). Results are from one experiment, representative of n=2
distinct experiments performed in identical conditions.
doi:10.1371/journal.pone.0002229.g005
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virtually no COX-2 labeling (data not shown).
Nuc binds to COX-2 with high affinity
Affinity between Nuc and COX-2 [27] was confirmed in
neutrophils by incubating sepharose beads coated with hrNuc with
lysates obtained from resting- or PMA-stimulated neutrophils.
COX-2 co-immunoprecipitated along with hrNuc, assessed by
western immunoblottings (Fig. 5A). Chelation of Ca
2+ with 5 mM
EGTA did not prevent immunoprecipitation of COX-2 by hrNuc
(Fig. 5B), indicating that the association between the two proteins
does not chiefly rely on availability of Ca
2+. Presence of Nuc and
COX-2 within the same organelle was also demonstrated by
immunoprecipitation experiments. An aliquot of Nuc-positive
fractions resulting from nitrogen cavitation experiments (right
panel of Fig. 2A, fraction 11) was incubated with anti-Nuc
polyclonal antibodies covalently-linked to magnetic beads. These
anti-Nuc-coated beads specifically immunoprecipitated structures
which, in addition to containing Nuc, also contained COX-2 and
GRP-78 (Fig. 5C), showing that the organelles containing Nuc also
harbor COX-2 and Golgi/ER structures. Finally, direct associa-
tion between Nuc and COX-2 was demonstrated by two ways
through immunoprecipitation experiments. First, COX-2-express-
ing neutrophil lysates were treated with an anti-Nuc antibody and
presence of COX-2 in the immunoprecipitates was confirmed by
western immunoblots (Fig. 5D, left panel). Second, lysates were
conversely treated with an anti-COX-2 antibody, and Nuc could
also detected in immunoprecipitates (Fig. 5D, right panel).
Together, these results demonstrate co-localization, proximity
and direct association between Nuc and COX-2 in human
neutrophils.
Nucleobindin increases cyclooxygenase-2-dependent
prostaglandin E2 generation
We addressed the intriguing possibility that Nuc may impact on
COX-2activity,firstbyusinganinvitroenzymaticassaywithpurified
human recombinant (hr)COX-2. In this highly-simplified system,
addition of hrNuc increased the generation of PGE2 in a
concentration-dependent fashion, up to 4 fold over basal levels
(Fig. 6A). Pre-treatment of Nuc with the anti-Nuc polyclonal
antibody prevented the increase in PGE2 production (Fig. 6B),
pointing to a specific implication of Nuc in this process. In addition,
the Nuc-enhanced PGE2 production was entirely prevented by the
specific COX-2 inhibitor NS-398, confirming a COX-2 mediated
event (Fig. 6B). These results, showing enhancing impact of Nuc on
COX-2-dependent PGE2 production, support the concept of a
physiologically significant interaction between Nuc and COX-2.
This point was specifically addressed: lysates from COX-2-
expressing neutrophils were stimulated with AA, alone or in the
presence of increasing quantities of hrNuc, and production of PGE2
was measured. In these experiments,exogenous hrNucincreased the
production of PGE2 in a concentration-dependent fashion, up to 5-
fold over basal levels (Fig. 7A). And, once again, the Nuc-enhanced
PGE2 production wasprevented by pre-incubation of hrNucwith an
anti-Nuc antibody, or by the presence of NS-398 (Fig. 7B),
confirming a Nuc and COX-2-mediated event. Further evidence
of a functionally relevant interaction between Nuc and COX-2 was
obtained by transfecting Nuc into intact COX-2-expressing
neutrophils. Cells were transfected either with full-length hrNuc or
with hrNuc lacking the COX-binding domain (NucDCBD), then
stimulatedwithAA.Ascanbeappreciated inFig.7C,additionoffull
length hrNuc specifically caused a significant increase in PGE2
biosynthesis by neutrophils, while NucDCBD was ineffective.
Figure 6. Nuc increases COX-2-dependent PGE2 biosynthesis. A) Recombinant human (hr)COX-2 (1 U/sample) alone or in presence of
indicated amounts of hrNuc, were incubated with AA. PGE2 production was measured by ELISA. Results are expressed as percentages of maximum
production and are the mean6s.e.m. of four separate experiments performed in identical conditions. B) hrNuc (10 mg) was treated with a polyclonal
anti-Nuc antibody prior to incubation with hrCOX-2. The COX-2 specific inhibitor NS-398 (50 mM) was used to confirm a COX-2-mediated event.
Results are expressed as percentage of inhibition of PGE2 production, when compared to the production obtained in the absence of antibody or
inhibitor (mean6s.e.m., n=4. *: significantly higher than samples incubated without hrNuc; **: significantly higher than samples incubated with
2.0 mg hrNuc or less).
doi:10.1371/journal.pone.0002229.g006
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All approaches taken, be that cavitation coupled to subcellular
fractionation,electronmicroscopy,immunofluorescence,orconfocal
microscopy, indicated that Nuc mainly clusters in a central place in
the vicinity of -but distinct from- nuclear lobes, a region in which the
Golgi resides [46], and in a small number of nearby additional spots,
consistent with ER localization. Conversely, Nuc does not appear to
be present in granules or in the plasma membrane of human
neutrophils. It remains possible that lower levels of Nuc could be
found elsewhere, but the thorough approach undertaken herein
strongly points to a Golgi/ER localization for Nuc.
In different cell types , COX-2 has also been reported to localize
in the Golgi and ER. In addition to an N-terminal signal peptide
which causes initial ER integration during translation, a C-
terminal KDEL-like signal (PTEL) is also present in the structure
of COX-2 and thought to be recognized by a membrane-bound
receptor that continually retrieves the proteins from later
compartments of the secretory pathway and returns them to the
ER [47]. Results from the present study further document a Golgi
and ER localization for Nuc and COX-2 in neutrophils. In
addition, activated cPLA2, mPGES-1 and TXA2- synthase, in fact
all enzymes of the prostanoid biosynthesis machinery, were also
found in the same Golgi- and ER-containing fractions, along with
Nuc and COX-2. Fractionation procedures and microscopy
experiments further showed that, in human neutrophils, Nuc
and COX-2 can localize in proximity of each other. Finally,
immunoprecipitations and pull down assays each confirmed direct
interaction and a high affinity between Nuc and COX-2.
When focusing on the delineation of a physiologically-relevant
function for this high-affinity association, hrNuc specifically
increased the COX-2-mediated formation of PGE2, in three
distinct settings: purified COX-2, cell lysates, and transfected
intact cells. Amongst all known prostanoids, purified human
neutrophils only release PGE2 and TXA2 from COX-2 activity
[3]. In turn, only PGE2 was considered in this study as it can be
non-enzymatically produced from COX-generated PGH2. The
increase in COX-2-dependent PGE2 generation was concentra-
tion-dependent and reached up to five fold increase, relative to
basal levels. Also, presence of a putative COX-binding domain
[27] was necessary for increasing PGE2 production. These
experiments could not, however, take into consideration crucial
factors such as the micro-environment, compartmentalization, or
cellular architecture. Moreover, post-translational modifications of
native Nuc, absent in hrNuc, may affect interactions in an as of yet
unknown fashion. In this regard, Nuc does not appear to be N-o r
O-linked glycosylated, but possesses up to 10 potential phosphor-
ylation sites including three protein kinase C sites which may well
impact on its conformation and propensity to associate with other
proteins, including COX-2 [26]. In turn, further studies
documenting a thorough determination of the stoichiometry of
this association, as well as of involvement of final-step enzymes
(e.g., mPGES-1, TXA2-S), which will most likely require
combinations of cell-free and cell line- based experimental set
ups, will be necessary before the architecture of this pivotal
enzymatic complex can be progressively unveiled. Nonetheless,
results obtained indicate a high affinity between Nuc and COX-2.
In summary, we found that Nuc mainly localizes in the Golgi
and ER of human neutrophils, along with COX-2 and other
enzymes involved in prostanoid generation. Nuc can associate with
COX-2 with high affinity and increase the resulting PGE2
generation. The potential role of Nuc in the regulation of PGE2
Figure 7. Nuc increases PGE2 biosynthesis in a COX-2-dependent manner in human neutrophils. A) COX-2-expressing neutrophil
extracts were incubated with AA (10 mM) for 30 min, alone or in the presence of indicated quantities of hrNuc. PGE2 production was measured by
ELISA. Results are expressed as percentages of maximum PGE2 production (mean6s.e.m., n=3). B) Left bar; hrNuc (1 mg) was treated with a
polyclonal anti-Nuc antibody prior to incubation with the cellular extracts. Right bar; the COX-2 specific inhibitor NS-398 (50 mM) was used to confirm
a COX-2-mediated PGE2 biosynthesis. Results are expressed as inhibition of PGE2 production, when compared to the production obtained in the
absence of antibody or inhibitor (mean %6s.e.m., n=4). C) Bar graph; GM/TNF-treated neutrophils were transfected with full-length hrNuc, or lacking
a COX-binding domain (NucDCBD) using the Pro-Ject procedure as described in Experimental procedures, then stimulated with AA (10 mM). PGE2
production was measured by ELISA. (mean6s.e.m., n=3. *: significantly higher than samples incubated without Nuc). Western immunoblots; Cells
treated as described above were processed for the determination of cellular COX-2, Nuc, hrNuc and NucDCBD protein levels. Note that hrNuc
migrates higher than endogenous Nuc (or NucDCBD), because of the signal peptide sequence still being present. Immunoblots are from one
experiment, typical of three independent experiments performed in identical conditions.
doi:10.1371/journal.pone.0002229.g007
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and the present report might be a first step in a characterization of
this pivotal enzymatic complex.
Supporting Information
Movie S1 3D visualization of Nuc localization. A 45 sec video
sequence, based on confocal data obtained on the sample
presented in B), illustrates the 3 dimensional localization of Nuc
in the center of one human neutrophil. Nuc is clearly observed in
the center of the cell and within a limited number of vesicles in the
vicinity of the nucleus, typical of the Golgi and endoplasmic
reticulum, respectively. The second half of the video is in ‘edge’
mode, which delineates the contours of localization of Nuc, putting
in evidence a central reservoir at the center of the cell as well as
close-by endoplasmic reticulum vesicles.
Found at: doi:10.1371/journal.pone.0002229.s001 (3.36 MB
MOV)
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